Earnings Call Summary | SpringWorks Therapeutics(SWTX.US) Q1 2024 Earnings Conference
Earnings Call Summary | SpringWorks Therapeutics(SWTX.US) Q1 2024 Earnings Conference
The following is a summary of the SpringWorks Therapeutics, Inc. (SWTX) Q1 2024 Earnings Call Transcript:
以下是SpringWorks Therapeutics, Inc.（SWTX）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
SpringWorks Therapeutics reported revenue of $21 million after the successful U.S. launch of OGSIVEO.
Operating expenses have increased due to commercial activities supporting OGSIVEO's launch.
By the end of the first quarter of 2024, the company had $573 million in cash, cash equivalents, and marketable securities.
SpringWorks Therapeutics报告称，在美国成功推出OGSIVEO后，收入为2100万美元。
由于商业活动支持OGSIVEO的推出，运营费用有所增加。
到2024年第一季度末，该公司拥有5.73亿美元的现金、现金等价物和有价证券。
Business Progress:
业务进展：
The company has focused on establishing OGSIVEO as a new standard of care for desmoid tumor patients.
The rollout of mirdametinib for NF1-PN is in progress with prospective approval by 2025.
Research is being advanced in multiple areas like ovarian granulosis cell tumors, multiple myeloma, MAPK mutant and Hippo mutant solid tumors.
OGSIVEO is well-received and often preferred over other treatments due to its superior efficacy and tolerability.
The FDA approved their supplemental NDA for 150-milligram and 100-milligram OGSIVEO tablets, enhancing patient convenience.
Steady progress is being made in the Phase 2 trial of nirogacestat for ovarian granulosa cell tumors, and the Phase 1 study for SW-682 for cancers with Hippo pathway mutations.
The European Medicines Agency validated their marketing authorization applications for nirogacestat, making it a potential first approved therapy for desmoid tumors in the EU.
A rolling NDA submission for mirdametinib is underway, with completion expected by the end of June.
该公司一直致力于将OGSIVEO确立为硬膜肿瘤患者的新护理标准。
用于 NF1-PN 的米达替尼的推出正在进行中，预计将在 2025 年获得批准。
卵巢颗粒细胞肿瘤、多发性骨髓瘤、MAPK突变体和Hippo突变体实体瘤等多个领域的研究正在取得进展。
OGSIVEO 广受好评，由于其卓越的疗效和耐受性，通常比其他疗法更受青睐。
美国食品药品管理局批准了150毫克和100毫克OGSIVEO片剂的补充保密协议，从而提高了患者的便利性。
nirogacestat治疗卵巢颗粒细胞肿瘤的2期试验和针对Hippo途径突变癌症的 SW-682 的1期研究正在取得稳步进展。
欧洲药品管理局验证了其nirogacestat的上市许可申请，这使其有可能成为欧盟首个获得批准的硬质肿瘤疗法。
米达替尼的滚动保密申请正在提交中，预计将于6月底完成。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。